ABVC BioPharma, Inc. develops drugs and medical devices to fulfill unmet medical needs in the United States.The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer. ABV-1504 has completed Phase II clinical trials for major depressive disorders. ABV1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
